Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nickerson, T.
Right arrow Articles by Pollak, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nickerson, T.
Right arrow Articles by Pollak, M.
[Cancer Research 61, 6276-6280, August 15, 2001]
© 2001 American Association for Cancer Research

Tumor Biology

In Vivo Progression of LAPC-9 and LNCaP Prostate Cancer Models to Androgen Independence Is Associated with Increased Expression of Insulin-like Growth Factor I (IGF-I) and IGF-I Receptor (IGF-IR)1

Tara Nickerson, Francis Chang, Donald Lorimer, Steven P. Smeekens, Charles L. Sawyers and Michael Pollak2

Cancer Prevention Research Unit of the Jewish General Hospital and McGill University, Montreal, Quebec, H3T 1E2 Canada [T. N., M. P.]; Department of Hematology-Oncology, UCLA School of Medicine, Los Angeles, California, 90095-1678 [F. C., C. L. S.]; and Axys Pharmaceuticals, Inc., San Francisco, California 94080 [S. P. S., D. L.]

Androgen deprivation therapies for metastatic prostate cancer are useful initially, but progression to androgen independence usually results in relapse within 2 years. The molecular mechanisms underlying the clinically important transition from androgen dependence to androgen independence are poorly described. Several lines of investigation have suggested that insulin-like growth factors (IGFs) are involved in the biology of prostate cancer, but little is known about their relevance to progression to androgen independence. We used three in vivo models of androgen-dependent (AD) human prostate cancer to study this issue. Progression to androgen-independent (AI) growth was associated with a 60-fold increase in expression of IGF-I mRNA in LAPC-9 xenografts and a 28-fold increase in IGF-I expression in LNCAP xenografts, relative to the initial AD neoplasms. IGF type I receptor (IGF-IR) mRNA levels were ~2.5-fold and ~5-fold higher, respectively, in AI LAPC-9 and LNCaP tumors compared with the original AD neoplasms. AI growth of these xenografts was also associated with significant reductions in IGF binding protein-3 expression. LAPC-4 xenografts, which previously have been shown to exhibit molecular pathology related to HER-2/neu expression with progression to AI, showed relatively minor changes in expression of the genes investigated, but we nevertheless found evidence of increased IGF-IR phosphorylation with progression to androgen independence in this model. Taken together with prior observations, our results suggest that deregulation of expression of genes related to any one of several critical receptor tyrosine kinase regulatory systems, including IGF signaling, may confer androgen independence.




This article has been cited by other articles:


Home page
 J. Nutr.Home page
L.-H. Chen, J. Fang, Z. Sun, H. Li, Y. Wu, W. Demark-Wahnefried, and X. Lin
Enterolactone Inhibits Insulin-Like Growth Factor-1 Receptor Signaling in Human Prostatic Carcinoma PC-3 Cells
J. Nutr., April 1, 2009; 139(4): 653 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Schayek, K. Haugk, S. Sun, L. D. True, S. R. Plymate, and H. Werner
Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor-Dependent Manner
Clin. Cancer Res., March 1, 2009; 15(5): 1558 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M.-L. Zhu and N. Kyprianou
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells
Endocr. Relat. Cancer, December 1, 2008; 15(4): 841 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. S. Lyons, S. Rao, W. Balkan, J. Faysal, C. A. Maiorino, and K. L. Burnstein
Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer
Mol. Endocrinol., March 1, 2008; 22(3): 597 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Pandini, M. Genua, F. Frasca, S. Squatrito, R. Vigneri, and A. Belfiore
17{beta}-Estradiol Up-regulates the Insulin-like Growth Factor Receptor through a Nongenotropic Pathway in Prostate Cancer Cells
Cancer Res., September 15, 2007; 67(18): 8932 - 8941.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Dagvadorj, S. Collins, J.-B. Jomain, J. Abdulghani, J. Karras, T. Zellweger, H. Li, M. Nurmi, K. Alanen, T. Mirtti, et al.
Autocrine Prolactin Promotes Prostate Cancer Cell Growth via Janus Kinase-2-Signal Transducer and Activator of Transcription-5a/b Signaling Pathway
Endocrinology, July 1, 2007; 148(7): 3089 - 3101.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Fan, T. Yanase, H. Morinaga, T. Okabe, M. Nomura, H. Daitoku, A. Fukamizu, S. Kato, R. Takayanagi, and H. Nawata
Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor
J. Biol. Chem., March 9, 2007; 282(10): 7329 - 7338.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Fang, Q. Zhou, X.-l. Shi, and B.-h. Jiang
Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells
Carcinogenesis, March 1, 2007; 28(3): 713 - 723.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari
Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation
Cancer Res., February 1, 2007; 67(3): 1155 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. V. Silha, P. C. Sheppard, S. Mishra, Y. Gui, J. Schwartz, J. G. Dodd, and L. J. Murphy
Insulin-Like Growth Factor (IGF) Binding Protein-3 Attenuates Prostate Tumor Growth by IGF-Dependent and IGF-Independent Mechanisms
Endocrinology, May 1, 2006; 147(5): 2112 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Kawada, H. Inoue, T. Masuda, and D. Ikeda
Insulin-like Growth Factor I Secreted from Prostate Stromal Cells Mediates Tumor-Stromal Cell Interactions of Prostate Cancer.
Cancer Res., April 15, 2006; 66(8): 4419 - 4425.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. L. Goel, M. Breen, J. Zhang, I. Das, S. Aznavoorian-Cheshire, N. M. Greenberg, A. Elgavish, and L. R. Languino
{beta}1A Integrin Expression Is Required for Type 1 Insulin-Like Growth Factor Receptor Mitogenic and Transforming Activities and Localization to Focal Contacts
Cancer Res., August 1, 2005; 65(15): 6692 - 6700.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Bianco, T. Troiani, G. Tortora, and F. Ciardiello
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S159 - S171.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Xia, S. R. Kumar, R. Masood, S. Zhu, R. Reddy, V. Krasnoperov, D. I. Quinn, S. M. Henshall, R. L. Sutherland, J. K. Pinski, et al.
EphB4 Expression and Biological Significance in Prostate Cancer
Cancer Res., June 1, 2005; 65(11): 4623 - 4632.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. D. Wu, A. Odman, L. M. Higgins, K. Haugk, R. Vessella, D. L. Ludwig, and S. R. Plymate
In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors
Clin. Cancer Res., April 15, 2005; 11(8): 3065 - 3074.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Pandini, R. Mineo, F. Frasca, C. T. Roberts Jr., M. Marcelli, R. Vigneri, and A. Belfiore
Androgens Up-regulate the Insulin-like Growth Factor-I Receptor in Prostate Cancer Cells
Cancer Res., March 1, 2005; 65(5): 1849 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. T. Arnold, H. Le, K. K. McFann, and M. R. Blackman
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells
Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E573 - E584.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
S. L. Krueckl, R. A. Sikes, N. M. Edlund, R. H. Bell, A. Hurtado-Coll, L. Fazli, M. E. Gleave, and M. E. Cox
Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model
Cancer Res., December 1, 2004; 64(23): 8620 - 8629.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Rubinstein, G. Idelman, S. R. Plymate, G. Narla, S. L. Friedman, and H. Werner
Transcriptional Activation of the Insulin-Like Growth Factor I Receptor Gene by the Kruppel-Like Factor 6 (KLF6) Tumor Suppressor Protein: Potential Interactions between KLF6 and p53
Endocrinology, August 1, 2004; 145(8): 3769 - 3777.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. H. Ngo, R. J. Barnard, T. Anton, C. Tran, D. Elashoff, D. Heber, S. J. Freedland, and W. J. Aronson
Effect of Isocaloric Low-Fat Diet on Prostate Cancer Xenograft Progression to Androgen Independence
Cancer Res., February 15, 2004; 64(4): 1252 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al.
A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo
Cancer Res., December 15, 2003; 63(24): 8912 - 8921.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
D. B. Boyd
Insulin and Cancer
Integr Cancer Ther, December 1, 2003; 2(4): 315 - 329.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Uemura, H. Ishiguro, N. Nakaigawa, Y. Nagashima, Y. Miyoshi, K. Fujinami, A. Sakaguchi, and Y. Kubota
Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor
Mol. Cancer Ther., November 1, 2003; 2(11): 1139 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kiyama, K. Morrison, T. Zellweger, M. Akbari, M. Cox, D. Yu, H. Miyake, and M. E. Gleave
Castration-Induced Increases in Insulin-Like Growth Factor-Binding Protein 2 Promotes Proliferation of Androgen-independent Human Prostate LNCaP Tumors
Cancer Res., July 1, 2003; 63(13): 3575 - 3584.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Jiang and Z. Wang
Identification of Androgen-Responsive Genes in the Rat Ventral Prostate by Complementary Deoxyribonucleic Acid Subtraction and Microarray
Endocrinology, April 1, 2003; 144(4): 1257 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Letsch, A. V. Schally, R. Busto, A. M. Bajo, and J. L. Varga
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers
PNAS, February 4, 2003; 100(3): 1250 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. M. Adam, J. Kim, J. Lin, A. Orsola, L. Zhuang, D. C. Rice, and M. R. Freeman*
Heparin-Binding Epidermal Growth Factor-Like Growth Factor Stimulates Androgen-Independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function
Endocrinology, December 1, 2002; 143(12): 4599 - 4608.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. O. Hellawell, G. D. H. Turner, D. R. Davies, R. Poulsom, S. F. Brewster, and V. M. Macaulay
Expression of the Type 1 Insulin-like Growth Factor Receptor Is Up-Regulated in Primary Prostate Cancer and Commonly Persists in Metastatic Disease
Cancer Res., May 1, 2002; 62(10): 2942 - 2950.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
J Natl Cancer Inst, December 19, 2001; 93(24): 1852 - 1857.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.